US Pharm. 2012;37(11):46.

Par Pharmaceutical Companies, Inc., announced that it has entered into agreements with Watson Pharmaceuticals, Inc., and Actavis Group to purchase for cash five generic products that are currently marketed in the U.S. by Watson or Actavis; eight Abbreviated New Drug Applications currently awaiting regulatory approval; and a generic product in late-stage development. The closing of the purchase agreements is contingent upon the closing of Watson’s acquisition of Actavis.

The five currently marketed products include morphine sulfate extended-release capsules (the generic version of Kadian); fentanyl transdermal system CII (generic of Duragesic); nifedipine extended-release tablets (generic of Adalat CC); diltiazem hydrochloride extended-release capsules (generic of Cardizem CD); and metoclopramide hydrochloride tablets (generic of Reglan). Par expects to begin shipping these products to the trade immediately following the closing of the acquisition.